PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
/ 111 items
#XY Event-Driven Stocks↓
Veradermics’ Oral Hair Loss Pill Scores Major Win in Late-Stage Trial
Veradermics’ hair pill VDPHL01 showed strong results, growing 30+ hairs/cm in trials, safe, and may become a new baldness treatment.
Oruka’s Long-Acting Psoriasis Drug Hits 63.5% Complete Skin Clearance in Mid-Stage Trial
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Eli Lilly Acquires Ajax Therapeutics to Advance New Treatment for Rare Blood Cancers
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
Sun Pharma Acquires Organon in $11.75 Billion Deal – India’s Biggest Overseas Pharma Buy
Sun Pharma will buy Organon for $11.75B, boosting global reach, women’s health, and specialty drugs, and creating a $12.4B annual revenue pharma giant.
Radoff-JEC Group Boosts Seer Takeover Bid to $2.35
Investors offered to buy Seer for $2.35/share plus extra future payout; stock rose after takeover bid. Board responds by May 2.